Introduction
In the last two decades many cancer treatments have been developed to offer prolonged survival to patients with metastatic cancer. These new treatments have significantly improved survival of certain cancers [1] . However, there are still certain types of high unmet need advanced and/or metastatic tumors, associated with poor prognosis and a median survival less than a year, for which therapies have added only modest numerical increase in survival. Lung, pancreatic, liver, and gastric cancer, certain forms of aggres-tem levels must be provided with the necessary information both from a clinical and an economical perspective.
In particular, there is a relevant need to define objective methodologies comparing the cost-effectiveness of drugs in oncology. The typical questions for health economists are: "At certain price conditions, is drug X cost-effective vs. drug Y, for a given cancer?" and "Is this cost-effectiveness of drug X acceptable?" A number of robust methodologies exist to address these question, ranging from cost-effectiveness analysis to cost-utility analysis, using progression free survival, overall survival, quality adjusted survival (with QALYs, quality adjusted life years) as main outcomes [11] [12] [13] . Common problems with these analyses are that they are cumbersome and need extensive data of quality of life, further line treatments, and end of life costs for the analysis. At the time of decision these data are often missing and QALYs are impossible to analyze [14] . However, policy makers and budget holders, have other difficult questions to answer, that are beyond the one-to-one comparison in a single disease: "cost of drug X in cancer A is aligned to cost of drug Y in cancer B, in a way that the cost of both drugs reflect their own value"? This question is crucial for those public or private institutions ensuring that investments must be consistent across conditions, in order to avoid access inequalities.
A simple and easy-to-use method should be developed to facilitate the decision makers in determining how to allocate the budget for such serious diseases. For this purpose, the present study aims to suggest a method to compare innovative therapies for high unmetneed solid tumours, considering their drug costs in relation with their clinical benefits.
This article represents an attempt to define a method to address this issue. More specifically, this method was used to compare the economic value of nano-albumin bound paclitaxel (nab-paclitaxel, recently approved by the European Medicines Agency in pancreatic cancer) [15, 16] , versus other therapies approved in high-unmetneed solid tumours. The analysis correlates the cost of treatment of a group of drugs approved for high-unmet need cancer types, with the additional overall survival (OS) and progression free survival (PFS) benefits provided by the drugs.
Methods
This analysis aims to evaluate the cost profile of nano-albumin bound paclitaxel (nab-paclitaxel) in pancreatic cancer versus other therapies in high-unmet need solid tumour indications. The analysis was performed for four Nordic countries (Norway, Sweden, Denmark and Finland) using the health care funder's perspective. In this analysis treatment costs of drugs were related to their clinical benefit, expressed as absolute efficacy (cost per month of PFS and OS) and relative efficacy versus trial comparator (% PFS and OS months gained).
Drug selection
Data regarding the drugs' clinical efficacy (comparator, treatment duration, PFS, OS), posology, co-administration of other cancer therapies (i.e. chemotherapy) and duration of treatment was retrieved from the European Medicine Agency (EMA) website [17] , using European Public Assessment Reports (EPARs). Where clinical data was not available, a supplementary published literature search was performed to fill the gap [see Table 1 for references].
The drug searches were performed on March 1st, 2015. For this analysis, we included drugs which: (i) had received the EMA approval after 2000; (ii) had been authorized in at least one metastatic cancer indication; (iii) were indicated in a high unmet need condition (hereby defined as a condition for which the drug comparator in the registration trial achieved a maximum OS of 12 months).
Posology and duration of treatment
In order to calculate cost of cancer treatments, standard posology, as reported in EPARs (and relative clinical trials), was used. Calculation of posology was determined assuming to treat a hypothetical patient of 65 Kg, with body surface area (BSA) of 1.73 m 2 . Duration of treatment was retrieved from EPARs, and if not available in the EPARs, from relative published literature [see Table 1 for references].
For those treatment cases in which the amount of active substance exceeded the required posology, the amount of exceeding drug was assumed wasted. For example, if a certain treatment in a hypothetical patient required 2.8 vials, costs were calculated considering 3 vials, assuming that the remaining amount of drug (0.2 vials) could not be used to treat another patient. Duration of treatment was assumed to be equal to that observed in the clinical trial settings.
Costs
The total cost of each treatment was calculated using pharmacy purchasing price for Denmark [18] , Norway [19] and Sweden [20] , and wholesaler prices for Finland [21] (which are comparable to pharmacy prices in the other countries). For Finland, wholesaler prices were calculated multiplying the public prices reported in the official source [21] by a coefficient used to convert public prices into wholesaler prices [extrapolated from [22] ].
Prices were converted from local currencies to Euros (using average exchange rates over the period January-March 2015, 3 months: 1 Danish Crown: D 0.1340; 1 Norwegian Crown: D 0.1139; 1 Swedish Crown: D 0.1090 [23] ). For those therapies having multiple packaging and/or doses, same amount of therapy could be associated to different treatment costs. In this case, the lowest cost achievable was used for the analysis.
Costs of drugs given in association with the study drug (e.g. gemcitabine, co-administered to nab-paclitaxel, or cisplatin, coadministered to S-1) were included in the analysis. Finally, the total cost per patient was obtained for each treatment and for all the Nordic countries in analysis.
Tumor incidence data
Epidemiology data regarding incident tumor cases (in 2012, latest update) was retrieved for each analyzed Nordic country to estimate the size of the populations that could be treated, and to estimate the related economic impact [24] . The number of diagnosed cases (which took into account whether the therapy was indicated in a specific subgroup of patients, e.g. human epidermal growth factor receptor 2 [HER2] positive gastric cancer for trastuzumab and BRAF mutated in melanoma for vemurafenib) was then transformed in crude incidence rates (expressed number of cases per 100,000 inhabitants), using population data of the Nordic countries [25] . Crude incidence rates were finally used in correlation graphs (x-y scatterplots), where the size of the dots associated to a drug/condition was proportional to tumor incidence. The summary of tumor crude incidence rates is shown in Table 2 .
Analyses
With this analysis, we aimed to examine whether the incremental benefit provided by a drug, versus its trial comparator, predicted the monthly cost per OS/PFS month achieved. Costs per OS and PFS month (or TTP month if PFS was not available) were calculated Note: AUC = area under the curve. LD = loading dose. MD: maintenance dose. The analysis only includes treatments approved for newly diagnosed (first-line) patients, with the exception of ramucirumab, which is indicated after disease progression with chemotherapy [35] . Nevertheless, ramucirumab clinical data from second-line randomized trials were included as this therapy is indicated in a high-unmet need condition (gastric cancer) with a <12 months OS expectation for treatment-naïve patients (cfr S-1 and trastuzumab). dividing the overall cost of treatment (drug costs over the entire period) by the number of months of OS and PFS achieved with the treatment, respectively. Second, a linear regression analysis was performed (overall and by country) in order to evaluate dependency of cost per OS/PFS month on incremental benefit achieved. The incremental benefit was expressed as the relative improvement in OS/PFS achieved with the treatment, compared to its trial alternative. Robust regression was evaluated to test goodness of fit. For those cases with poor R 2 (<0.5), determined by observations with high leverages and residuals, a robust regression was attempted to re-calculate R 2 . Robust weighted regression excluded observations with >0.25 Cook distance and weighted the remaining observations according to their residual distances from the means.
Since treatment costs could be affected by patients' characteristics, a simple sensitivity analysis, based on variations of ±10% body surface area (BSA) and ±10% weight, compared to the base case assumption (BSA = 1.73 m 2 ; weight: 65 Kg), was performed to test analysis conclusions. Additional sensitivity analyses were conducted to evaluate results under the assumption of absence of drug wastage.
Analyses were performed for each country, and then aggregated calculating mathematical averages
Results
From EMA database, 42 drugs with at least one indication in solid tumours within 20 years were detected. Eleven of these (26.2%), met the selection criteria and were included in the analysis ( Fig. 1) : bevacizumab in non-small cell lung cancer (NSCLC), cetuximab in head and neck cancer (HNC), erlotinib in pancreatic cancer (PancC); ipilimumab in melanoma, nab-paclitaxel in PancC, pemetrexed in mesothelioma, ramucirumab in gastric cancer (or gastro-oesophageal junction) cancer, used as both in monotherapy and in combination; S-1 (tegafur/gimeracil/oteracil) in gastric cancer (GC); temsirolimus in renal cell carcinoma (RCC), trastuzumab in HER2 positive GC and vemurafenib in BRAF V600 mutationpositive melanoma (BRAF melanoma). Table 1 reports the information extracted from EPARs [15, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and from published clinical trials [see Table 1 for references] , which was used to calculate treatment costs and related outcomes. Except for three therapies (temsirolimus, ipilimumab and vemurafenib), the remaining agents are administered in combination with chemotherapy and compared versus chemotherapy alone (i.e. tested as add-on therapy trials). Only ipilimumab is administered up to the maximum number of cycles (N = 4), while the remaining therapies are discontinued at time of intolerance or disease progression. Median PFS and OS in the comparator arm (proxy of disease prognosis with standard, alternative options) were 3.5 and 7.4 months, respectively, confirming the high level of unmet clinical needs for these conditions Table 3 reports the overall drug costs of the chosen therapies (including costs of drugs given in association, if any) in the Nordic countries. Small variability of average costs by country was observed (range: D 21,844-D 22,799), but it was not statistically significant (test F for variance: 0.9243). On the other side, internal cost variability was high (average of the four countries: D 1,761-D 66,243) with S-1 and erlotinib being the less expensive treatments, and ipilimumab and vemurafenib the most expensive ones. Economic impact of chemotherapies given in association to the study drugs was not negligible, especially for erlotinib, and nab-paclitaxel, which are co-administered with gemcitabine. Tables 4 and 5 show results of the cost per OS and PFS months gained respectively. Considering the average of the four Nordic countries, the drug associated with the lowest cost per OS was S-1 (D 205 per OS month gained), while the one with the highest was ipilimumab, (D 6,642 per OS month gained). The same trends were observed for all countries and for PFS, too. Average costs of nabpaclitaxel were D 1,684 per month of OS gained and D 2,602 per month of PFS gained. Figs. 2 and 3 show results of the regression analyses between cost per OS and PFS, respectively, and relative clinical benefits achieved versus trial comparator (Figs. 4 and 5 show results of correlation between costs and absolute benefit vs. trial comparator). Drugs positioned below the regression line had a cost-benefit profile more advantageous than the average. Analysis shows that drugs with higher relative benefit had generally higher costs per OS or PFS gained. A good prediction was found for OS (R 2 = 0.5359). For PFS analysis, linear regression was associated to poor fit (R 2 < 0.01). This was driven by two observations: ipilimumab (high residual) whose cost per PFS month was higher than the mean monthly costs, considered its relatively low PFS advantage, and vemurafenib (high leverage), whose PFS effect was higher than the mean, considered its cost. When robust regression was performed to minimize the effects of these unexpected observations, R 2 improved (0.1853), but remained much lower than for OS analysis. In both analyses, nab-paclitaxel was found not above regression lines, indicating that its cost was, at least, aligned to the clinical value offered Analysis of individual countries led to similar results for costs per OS and PFS month as shown in Figs. 6 and 7. Overall, results indicated that the overall cost of treatment for a drug reflected much better the OS endpoint achievement, rather than the PFS achievement.
Finally, one-way sensitivity analysis conducted on BSA and weight demonstrated some variability of results depending on patient's characteristics (Table 6 ). For drugs administered at fixed doses (temsirolimus, ipilimumab, vemurafenib) costs remained equal. Among drugs administered according to BSA or weight, treatment costs (and consequentially costs per OS and PFS) changed, a Since certain therapies are given in combination, they will account for a certain proportion of overall therapy costs. Drugs given as monotherapy account for the entire therapy costs (100%). 
Discussion
With the present analysis we aimed to address two main topics. First, we wanted to apply a simple quali-quantitative method to Note: N/A = not available. test whether the cost of a drug reflected its real clinical value, comparing pharmaceutical treatments approved for different oncology uses. Then we wanted to test the method, analyzing the practical case of the comparison between nab-paclitaxel versus other pharmacological treatments that could represent a good benchmark. Regarding the first topic, the analysis showed a good consistency between the sustained cost per OS month for a drug, and the relative OS increase offered by the drug vs. its trial comparator. According to this analysis, the higher is the clinical benefit, the higher is the cost per OS month, reflecting that budget holders in Nordic countries recognized consistently the value of the drugs. In this analysis, there were not large deviations from the expected trend. Unlike the OS analysis, the PFS analysis did not produce similar results, and the correlation between cost per PFS month and PFS relative benefit was mainly reduced by three drugs: ipilimumab, vemurafenib, ramucirumab. Ipilimumab was not associated to PFS advantage vs. trial comparator (2.86 months for ipilimumab; 2.76 placebo months for placebo; [44] ); vemurafenib was associated to a relevant, statistically significant PFS advantage (6.9 months for vemurafenib, vs. 1.6 months for placebo). Ramucirumab was not associated to a ≥0.25 Cook distance, however its cost per PFS month was higher than expected (average of all observations), if correlated to the relative PFS gain. These observations decreased the overall goodness of regression; moreover, regardless of these drugs, the relation between costs and PFS advantage was less clear than the OS relation, especially in certain countries (Norway and Sweden).
Several considerations can be made to explain this trend for the PFS analysis. In the ipilimumab trial, for example, OS was the clinically important and primary endpoint [44] . Likely, PFS could be an un-appropriate indicator for this drug. As a matter of fact, European Public Assessment Report does not report PFS data and clearly indicates that, if tolerated, the 4-cycles treatment should be continued and completed regardless of clinical response and early progression of the disease [29] , suggesting that the drug could have a kind of "delayed" effect, making PFS endpoint not extremely relevant. As a matter of fact, ipilimumab was the drug associated with the Size of bubbles is proportional to incidence rates [ Table 2 ]. ᭹ = 10-20 cases per 100,000 persons/year. Cost per OS month was found statistically dependent on OS gain vs. trial comparator.
highest OS advantage. Vemurafenib showed clear advantages in both PFS and OS, but it should be mentioned that the drug works only in a subgroup of patients (BRAF mutation patients). Similarly, trastuzumab, the other drug approved for use in a subpopulation (HER2+ gastric cancer) had a favorable ratio between costs and clinical benefit.
Focusing on nab-paclitaxel analysis, the drug cost per month of OS and PFS shows an overall favorable profile.
In our view, the quali-quantitative approach adopted in this analysis, with certain refinements, can be transformed into a good tool for decision makers to evaluate consistency of decisions across different oncology areas. Of course, the method cannot be considered a pure quantitative tool to anchor pricing and reimbursement decisions, but it can definitely help to avoid inconsistencies in budget allocation.
The major issue for such approach is to define the conditions/criteria to detect comparators for a certain therapies, particularly when deciding on how to allocate healthcare funds. In our analysis, we detected benchmarks for nab-paclitaxel using a set of criteria (i.e. solid tumors, drugs predominantly used in naïve patients, approved after year 2000, indicated in conditions associated to poor prognosis). We considered such selection criteria objective and appropriate to reduce the potential heterogeneity of comparisons. However, it could be argued that certain inclusion criteria were not used at all (e.g. include/exclude therapies indicated in specific patients' subgroups; include/exclude therapies based on the epidemiological impact of the associated condition). In our view, a good compromise on the number of selection criteria should be made, in order to ensure that comparison would remain valid and informative, and to keep a good number of therapies for comparison Our focus on objective criteria, such as median times-to-event, may introduce an oversimplification of important considerations in the selection of the most appropriate therapy: long-term survival benefits in small patient groups are not included in the analysis of medians of a patient population and underestimated in this approach when compared to real-life clinical practice. An evaluation of more comprehensive, and complex, health-economic analysis and studies is required to fully evaluate the benefit of these therapies across all sub-groups of patients. Additional considerations to opportunity costs and sensitivity analysis to address uncertainty in calculations, for example, are not included in this analysis but are standard to a thorough health-economic analysis.
In the present analysis, we used incidence data to estimate the potential patient population eligible for each treatment. Of course this approach is not extremely accurate to determine the budget impact associated to a certain therapy, as incidence and treatment duration are only two of the several factors determining the amount of drug use. A substantial number of patients with metastatic disease will not receive any chemotherapy at all due to usually old age or poor performance status [36] [37] [38] . On the other side, the more accurate approach, which would consist in determining the number of treated patients using national drug consumptions, would be equally difficult to implement. In fact, this analysis would require availability of national data, drug use during comparable periods of time (the use of a drug generally increases over time, and changes according to the availability of therapeutic alternatives). Finally, for certain therapies indicated for multiple conditions (e.g. Size of bubbles is proportional to incidence rates [ Table 2 ]. ᭹ = 10-20 cases per 100,000 persons/year. *Calculated through robust regression. Cost per PFS month was found statistically dependent on PFS gain vs. trial comparator. Size of bubbles is proportional to incidence rates [ Table 2 ]. ᭹ = 10-20 cases per 100,000 persons/year. Cost per PFS month was found statistically dependent on PFS gain vs. trial comparator.
trastuzumab, bevacizumab) it would be necessary to stratify use by indication, which is almost impossible with current available data.
Other refinements could increase the validity of this type of analysis. First, cost of treatment could be adjusted by dose intensity. As a matter of fact, in certain clinical trials, therapeutic dosage could have been decreased/increased to take into account risk-benefit factors. In the nab-paclitaxel pivotal trial, for example, dose intensity was 81% [16] . This correction was not applied in our analysis, as similar information was not available for all investigated therapies, but this aspect could be taken into account for further research using this approach. Second, prices used in these analyses should include all those forms of discounts/rebates (price-volume, cost sharing, payment by results agreements, etc.) that could affect costs of treatment. Finally, a systematic approach collecting all published evidence on a certain drug/indication, integrating or pooling clinical data with meta-analytic approaches, would make the analyses even more accurate, although this could affect its easiness-to-use.
Summarizing, we believe that decision making in healthcare, and specifically in oncology, is a very complicated process that cannot be converted into a "perfect" algorithm. Many factors related to the individuality of a disease and to the clinical needs of patients that cannot be simply measured or calculated with formulas. However, analytical tools, such as the one we proposed, could simply offer an additional hint to take decisions or to make sure that the decision respects certain rules
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